Jerome Fayette, MD, Centre Lèon Bèrard, Lyon, France, discusses the impact of the Phase II (NCT03526835) results of petosemtamab (MCLA-158) plus pembrolizumab in the current treatment landscape for head and neck squamous cell carcinoma (HNSCC). While the survival rate has not significantly improved, the therapeutic regimen of petosemtamab plus pembrolizumab is promising due to its high response rate in symptomatic patients. A longer follow-up is needed to evaluate the potential correlation between response rate and overall survival (OS). Advancing from Phase II to future Phase III trials is likely to demonstrate an increase in overall survival compared to other combinations, such as pembrolizumab plus cetuximab, which have shown overall lower response and survival rates. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть